Cargando…

Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development

The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Markovic, Milica, Zur, Moran, Fine-Shamir, Noa, Haimov, Ester, González-Álvarez, Isabel, Dahan, Arik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151103/
https://www.ncbi.nlm.nih.gov/pubmed/32214015
http://dx.doi.org/10.3390/pharmaceutics12030295
_version_ 1783521172965556224
author Markovic, Milica
Zur, Moran
Fine-Shamir, Noa
Haimov, Ester
González-Álvarez, Isabel
Dahan, Arik
author_facet Markovic, Milica
Zur, Moran
Fine-Shamir, Noa
Haimov, Ester
González-Álvarez, Isabel
Dahan, Arik
author_sort Markovic, Milica
collection PubMed
description The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled-release (CR) drug product development. The solubility/dissolution and permeability of carvedilol (vs. metoprolol) were thoroughly studied, in vitro/in vivo (Octanol-buffer distribution coefficients (Log D), parallel artificial membrane permeability assay (PAMPA), rat intestinal perfusion), focusing on location-dependent effects. Carvedilol exhibits changing solubility in different conditions throughout the GIT, attributable to its zwitterionic nature. A biorelevant pH-dilution dissolution study for carvedilol immediate release (IR) vs. CR scenario elucidates that while the IR dose (25 mg) may dissolve in the GIT luminal conditions, higher doses used in CR products would precipitate if administered at once, highlighting the advantage of CR from the solubility/dissolution point of view. Likewise, segmental-dependent permeability was evident, with higher permeability of carvedilol vs. the low/high P(eff) marker metoprolol throughout the GIT, confirming it as a biopharmaceutical classification system (BCS) class II drug. Theoretical analysis of relevant physicochemical properties confirmed these results as well. A CR product may shift the carvedilol’s solubility behavior from class II to I since only a small dose portion needs to be solubilized at a given time point. The permeability of carvedilol surpasses the threshold of metoprolol jejunal permeability throughout the entire GIT, including the colon, establishing it as a suitable candidate for CR product development. Altogether, this work may serve as an analysis model in the decision process of CR formulation development and may increase our biopharmaceutical understanding of a successful CR drug product.
format Online
Article
Text
id pubmed-7151103
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71511032020-04-20 Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development Markovic, Milica Zur, Moran Fine-Shamir, Noa Haimov, Ester González-Álvarez, Isabel Dahan, Arik Pharmaceutics Article The main factors influencing the absorption of orally administered drugs are solubility and permeability, which are location-dependent and may vary along the gastrointestinal tract (GIT). The purpose of this work was to investigate segmental-dependent intestinal absorption and its role in controlled-release (CR) drug product development. The solubility/dissolution and permeability of carvedilol (vs. metoprolol) were thoroughly studied, in vitro/in vivo (Octanol-buffer distribution coefficients (Log D), parallel artificial membrane permeability assay (PAMPA), rat intestinal perfusion), focusing on location-dependent effects. Carvedilol exhibits changing solubility in different conditions throughout the GIT, attributable to its zwitterionic nature. A biorelevant pH-dilution dissolution study for carvedilol immediate release (IR) vs. CR scenario elucidates that while the IR dose (25 mg) may dissolve in the GIT luminal conditions, higher doses used in CR products would precipitate if administered at once, highlighting the advantage of CR from the solubility/dissolution point of view. Likewise, segmental-dependent permeability was evident, with higher permeability of carvedilol vs. the low/high P(eff) marker metoprolol throughout the GIT, confirming it as a biopharmaceutical classification system (BCS) class II drug. Theoretical analysis of relevant physicochemical properties confirmed these results as well. A CR product may shift the carvedilol’s solubility behavior from class II to I since only a small dose portion needs to be solubilized at a given time point. The permeability of carvedilol surpasses the threshold of metoprolol jejunal permeability throughout the entire GIT, including the colon, establishing it as a suitable candidate for CR product development. Altogether, this work may serve as an analysis model in the decision process of CR formulation development and may increase our biopharmaceutical understanding of a successful CR drug product. MDPI 2020-03-24 /pmc/articles/PMC7151103/ /pubmed/32214015 http://dx.doi.org/10.3390/pharmaceutics12030295 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markovic, Milica
Zur, Moran
Fine-Shamir, Noa
Haimov, Ester
González-Álvarez, Isabel
Dahan, Arik
Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title_full Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title_fullStr Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title_full_unstemmed Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title_short Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development
title_sort segmental-dependent solubility and permeability as key factors guiding controlled release drug product development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151103/
https://www.ncbi.nlm.nih.gov/pubmed/32214015
http://dx.doi.org/10.3390/pharmaceutics12030295
work_keys_str_mv AT markovicmilica segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment
AT zurmoran segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment
AT fineshamirnoa segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment
AT haimovester segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment
AT gonzalezalvarezisabel segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment
AT dahanarik segmentaldependentsolubilityandpermeabilityaskeyfactorsguidingcontrolledreleasedrugproductdevelopment